Kemwell signs agreement with Mercury Pharma Group


To manufacture tablets in its new production facility in Uppsala, Sweden

Kemwell AB, an Indian contract manufacturer of pharmaceuticals with facilities in India and Sweden, has agreed with Mercury Pharma Group to manufacture tablets for the company in its new state-of-the-art production facility in Uppsala, Sweden and to handle distribution of the products in the UK and Ireland.

Kemwell entered the European market six years ago with the acquisition of a facility from Pfizer, where it now manufactures tablets, suppositories and capsules. The company says strong business development has allowed it already to double production space.

‘This agreement shows that we are indeed competitive in Sweden in production. Our new modern facility gives great opportunities for pharmaceutical manufacture in collaboration with both new and existing customers,’ said Kemwell AB’s CEO Agneta Bergvall.

Sign up for your free email newsletter

Mercury Pharma Group is an international pharmaceutical company specialising in the sale of prescription drugs. The company’s products are marketed worldwide with a focus on Europe.